FDA declares that rare neurological disorder Guillain-Barré syndrome (GBS) is an important potential risk of Pfizer’s RSV vaccine; it’s imperative then that FDA demands Pfizer perform safety studies

FDA wrote: ‘Given the temporal association and biological plausibility, FDA agrees with the assessments of the investigators that these events were possibly related to study vaccine.’
SOURCE:

https://www.fda.gov/media/165623/download

e.g.:

Go to Dr Alexancer on Substack
Author: Dr. Paul Alexander